1
|
Cojocaru E, Thway K, Fisher C, Messiou C, Zaidi S, Miah AB, Benson C, Gennatas S, Huang P, Jones RL. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Res 2020; 40:7003-7007. [PMID: 33288595 DOI: 10.21873/anticanres.14725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 11/07/2020] [Accepted: 11/08/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma. PATIENTS AND METHODS We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital. RESULTS Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months. CONCLUSION Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
Collapse
Affiliation(s)
| | - Khin Thway
- Sarcoma Unit, The Royal Marsden Hospital, London, U.K.,The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K
| | - Cyril Fisher
- The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.,Department of Musculoskeletal Pathology, University Hospitals Birmingham, Birmingham, U.K
| | - Christina Messiou
- The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.,Radiology Department, The Royal Marsden Hospital, London, U.K
| | - Shane Zaidi
- Sarcoma Unit, The Royal Marsden Hospital, London, U.K.,The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K
| | - Aisha B Miah
- Sarcoma Unit, The Royal Marsden Hospital, London, U.K.,The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K
| | | | | | - Paul Huang
- The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K
| | - Robin L Jones
- Sarcoma Unit, The Royal Marsden Hospital, London, U.K. .,The Institute of Cancer Research, Chester Beatty Laboratories, London, U.K.
| |
Collapse
|
2
|
Shenoy A, Surrey L, Jain P, Foster J, Straka J, Resnick A, Waanders A, Luo M, Li M, Kazahaya K, Bagatell R, Wojcik J, Pogoriler J. Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway. Pediatr Dev Pathol 2019; 22:594-598. [PMID: 31335288 DOI: 10.1177/1093526619864230] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Sclerosing epithelioid fibrosarcoma (SEF) is an uncommon neoplasm that rarely presents in bone. It is characterized by epithelioid cells arranged in nests and single-file cords within a sclerotic stromal background which may mimic neoplastic bone. SEF harbors an EWSR1 translocation, which may complicate its distinction from Ewing sarcoma in cases with histomorphologic overlap. We present a diagnostically challenging case of SEF in the mandible of a 16-year-old girl. Our experience highlights the lack of specificity of traditional morphology and EWSR1 break-apart fluorescent in situ hybridization. Open-ended RNA-based fusion gene testing coupled with MUC4 immunohistochemistry aided the eventual diagnosis in this case. Herein, we report the third case of SEF with EWSR1-CREB3L3 translocation and show that this fusion leads to aberrant upregulation of the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway in heterologous cell models.
Collapse
Affiliation(s)
- Archana Shenoy
- University of Florida College of Medicine, Gainesville, Florida
| | - Lea Surrey
- Children's Hospital of Philadelphia, Pathology, Immunology and Laboratory medicine, Philadelphia, Pennsylvania
| | - Payal Jain
- Children's Hospital of Philadelphia, Center for Data Driven Discovery in Biomedicine, Philadelphia, Pennsylvania
| | - Jessica Foster
- Children's Hospital of Philadelphia, Division of Oncology, Pediatrics, Philadelphia, Pennsylvania
| | - Joshua Straka
- Children's Hospital of Philadelphia, Center for Data Driven Discovery in Biomedicine, Philadelphia, Pennsylvania
| | - Adam Resnick
- Children's Hospital of Philadelphia, Center for Data Driven Discovery in Biomedicine, Philadelphia, Pennsylvania
| | - Angela Waanders
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Minjie Luo
- Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Marilyn Li
- Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Ken Kazahaya
- Children's Hospital of Philadelphia, Department of Clinical Otorhinolaryngology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
| | - Rochelle Bagatell
- Children's Hospital of Philadelphia, Division of Oncology, Pediatrics, Philadelphia, Pennsylvania
| | - John Wojcik
- University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Jennifer Pogoriler
- Children's Hospital of Philadelphia, Pathology, Immunology and Laboratory medicine, Philadelphia, Pennsylvania
| |
Collapse
|